Inspira™ Announces Start of Production of the INSPIRA™ ART100
RA'ANANA,

The INSPIRA ART100 device is being contract manufactured by a leading technology company that provides high-technology electronic assembly solutions for the medical, aero-space and aviation, communications and defense industries. The manufacturer has commenced with the production and assembly of the first batch of INSPIRA ART100 devices, which will be used for deployment in several initial sites, subject to U.S. Food and Drug Administration (FDA) regulatory clearance.
About Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to
For more details:
Public Relations Manager
Inspira Technologies
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved.
Logo - https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/inspira-announces-start-of-production-of-the-inspira-art100-302134546.html
SOURCE Inspira Technologies
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arcturus shares Phase 2 OTC data, unveils new mRNA platform
- Interactive Strength reports record Q2 results, raises Q3 guidance
- Viking Therapeutics plans $400M raise via stock and note offerings
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share